Episode Details
Back to Episodes
Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients?
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/four-new-glaucoma-developments-from-the-last-two-weeks-which-one-could-matter-most-for-patients
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients? Between August 21 and September 4, 2026, four glaucoma developments attracted attention: G01 / rhNGF-V2 neuroprotective eye drops Acid sphingomyelinase and ceramide metabolism as retinal ganglion-cell targets Optical coherence tomography angiography for earlier progression detection NCX 470, now called K-911, approaching United States regulatory review They are not equally important. One is already available as a diagnostic technology. One is close to possible approval but appears to be an incremental pressure-lowering improvement. The other two could eventually change the biology of glaucoma, but both remain uncertain and relatively early. This assessment uses information available through September 4, 2026, with the current regulatory status checked through September 11, 2026. > Important: The probabilities below are informed estimates, not clinical-trial results or regulatory predictions. “Changing care” means becoming sufficiently useful that it changes routine glaucoma management within approximately the next 5–10 years. At-a-Glance Comparison For the full table, please open this article on visualfieldtest.com. The Short Answer Most likely to help patients in the next 5–10 years NCX 470 / K-911 is the most likely to produce a measurable patient benefit because it has already completed large Phase 3 trials and has entered regulatory review. Most likely to improve glaucoma monitoring Optical coherence tomography angiography is the most immediately useful development. It may identify progression roughly two years before visual-field progression in some patients, although it is not perfect and does not directly treat glaucoma. () Highest upside G01 / rhNGF-V2 has the greatest potential upside because it aims to protect retinal ganglion cells independently of intraocular pressure. However, its current evidence is much weaker than the evidence supporting NCX 470. Most interesting biological discovery The acid sphingomyelinase–ceramide pathway may reveal a new way to protect retinal ganglion cells, but it is still a target rather than a treatment. --- G01 / rhNGF-V2 Neuroprotective Eye Drops What was reported? G01 is an investigational eye drop being developed in China for optic nerve injury associated with open-angle glaucoma. A Phase 2 study was updated on August 24, 2026, after being first posted on August 20, just outside the requested date range. The randomized, double-masked study plans to enroll approximately 90 patients with progressing primary open-angle glaucoma. It compares G01 concentrations of 100 micrograms per milliliter and 200 micrograms per milliliter with placebo. The study’s primary outcome is change in visual-field mean deviation after approximately 24 weeks of treatment, with additional structural, electrophysiological, pharmacokinetic, and immunogenicity measurements. Completion is estimated for late 2027. () A separate Phase 1 study in healthy volunteers is testing single and repeated doses of 100, 200, and 400 micrograms per milliliter. No public clinical efficacy results were available by September 4, 2026. () What is rhNGF-V2 supposed to do? Nerve growth factor is a neurotrophic protein involved in neuronal survival and repair. The goal is not